Broad cross-presentation of the hematopoietically derived PR1 antigen on solid tumors leads to susceptibility to PR1-targeted immunotherapy.
Alatrash G, Mittendorf EA, Sergeeva A, Sukhumalchandra P, Qiao N, Zhang M, St John LS, Ruisaard K, Haugen CE, Al-Atrache Z, Jakher H, Philips AV, Ding X, Chen JQ, Wu Y, Patenia RS, Bernatchez C, Vence LM, Radvanyi LG, Hwu P, Clise-Dwyer K, Ma Q, Lu S, Molldrem JJ.
Alatrash G, et al.
J Immunol. 2012 Dec 1;189(11):5476-84. doi: 10.4049/jimmunol.1201221. Epub 2012 Oct 26.
J Immunol. 2012.
PMID: 23105141
Free PMC article.